Circadian peculiarities of antioxidant and membrane-protective properties of glutargin in acute chrono-determined paracetamol-induced hepatitis
DOI:
https://doi.org/10.24959/cphj.17.1426Keywords:
liver, circadian rhythm, hepatoprotectors, glutarginAbstract
Hepatobiliary system diseases take a leading position among diseases of the gastrointestinal tract. One of the main groups of drugs used for their treatment is hepatoprotectors. Active development of chronophysiology, chronopatology and chronopharmacology creates the possibility of determining chronoportraits of drugs. Considering the latter it allows significantly optimizing the pharmacotherapy.
Aim. To assess the circadian dependence of the antioxidant and membrane-protective activity of glutargin. The choice of the drug as the object of our study was made due to its frequent use in clinical practice.
Materials and methods. The study was conducted on the model of acute paracetamol-induced hepatitis in the following chronosimulated mode: in the morning (09.00), in the daytime (15.00), in the evening (21.00) and at night (03.00). The dose of paracetamol in the experiment was 1000 mg/kg in rats. Glutargin was administered in the therapeutic and preventive mode in the dose of 135 mg/kg, i.e. an hour before administration of paracetamol and 2 hours after it.
Results. The study conducted revealed the peculiarities of dysinchronosis of the prooxidant-antioxidant balance and the activity of cytolysis markers depending on the period of the day, in which paracetamol-induced hepatitis was simulated; it allowed determining the peculiarities of their correction with glutargin. The most distinct decrease in the AlAT and AsAT activity when using glutargin was observed against the background of night and day simulation of hepatitis. It is probably due to the circadian peculiarities of antioxidant and membrane-stabilizing properties of this drug.
Conclusions. The circadian regulation peculiarities of prooxidant-antioxidant balance obtained with glutargin against the background of paracetamol-induced hepatitis should be considered when developing a comprehensive chronoportrait of this drug.
References
Shcherbinina, M. B. Primenenie gepatoprotektorov v sovremennoi meditcine. Available at: http://novosti.mif–ua.com/archive/issue–9091/article–9114/print.html
Mekhtiev, S. N., Okovityi, S. V., Mekhtieva, O. A. (2016). Lechashchii vrach, 8. Available at: http://www.lvrach.ru/2016/08/15436533/
Chernykh, V. P., Zupanetc, I. A., Kupnovitckaia, I.G. (2015). Klinicheskaiia farmatciia – Clinical pharmacy. Kharkiv : Zolotye stranitcy, NUPh, 1056.
Mann, D. A. (2014). Epigenetics in Liver Disease. Hepatology, 60 (4), 1418–1425.
Drogovoz, S. M. (2016). Khronofarmakologiia dliia vracha, provizora, studenta. Kharkiv: Titul, 376.
Drogovoz, S. M. et al. (2014). Khronofarmakologiia nagliadno (Khronofarmakologiia v tablitcakh i risunkakh). Kharkiv: Titul, 128.
Drogovoz, S. M., Kononenko, A. V., Timofeev, M.P. et al. (2013). Klinichna farmatsiia – Clinical pharmacy. Kharkiv, 327.
Drogovoz, S. M., Kalko, K. O., Zakharko, N. V. (2015). Optymizatsiia rezhymu pryiomu para–atsetaminofenolu z vrahkuvanniam biorytmiv pechinky. Kyiv, 4.
Matveev, A. V. (2013). Gepatoprotektory. Analiz mezhdunarodnykh issledovanii po preparatam gruppy lekarstv dlia pecheni.Simferopol: Arial, 384.
Chaika, L. A., Vertiaeva, O. N. (1997). Chelovek i lekarstvo, 184.
Zahaiko, A. L., Aleksandrova, K. V. (2014). Boikhimiia. Kharkiv: Fort, 728.
Frolov, V. M. (2003). Novosti meditciny i farmatcii, 8, 5–6.
Koveshnikov, O. V. (2003). Ukrainskyi medychnyi almanakh, 6 (1), 41–44.
Chubenko, S. S., Diadyk, A. I., Gaidukov, V. O. et al. (2002). Rossiiskii zhurnal gastroenterologii, gepatologii,koloproktologii, 1 (13), 36.
Mironov, A. N. et al. (2012). Rukovotstvo po provedeniiu doklinicheskikh issledovanii lekarstvennykh sredstv.Moscow: Grif i K, 944.
Rybolovlev, Yu. R., Rybolovlev, D. S. (1979). Doklady AN CCCR, 247 (6), 1513–1516.
Kamyshnikov, V. S. (2002). Spravochnik po kliniko–khimicheskoi laboratornoi diagnostike, 2 izd., 1. Minsk: Belarus, 382–395.
Voronina, L. M., Desenko, V. F., Kravchenko, V. M. et al. (1996). Posibnyk do laboratornykh i seminarskykh zaniat z biolohichnoi khimii. Kharkiv: Osnova, 432.
Koroliuk, M. A., Ivanova, L. I., Maiorova, I.G., Tokarev, V. E. (1988). Laboratornoe delo, 1, 99–101.
Semenenko, S. B. (2014). Bukovynskui medychyi visnyk, 18 (2(70)), 99–101.
Rebrova, O. Yu. (2006). Statisticheskii analiz meditcinskikh dannykh. Primenenie paketa prikladnykh program STATISTICA, 3 izd..Moscow: Media Sfera,312.
Stefanov, O. V. (2001). Doklinichni doslidzhennia likarskykh zasobiv. Kyiv: Avitsena, 528.
Kalko, K. O., Drohovoz, S. M., Zakharko, N. V., Yudkevych, T. K. (2016). Farmakolohiia ta likarska toksykolohiia, 1 (47), 81–86.
Zobnin, Yu. V. (2002). Otravlenie paratcetamolom: klinika, diagnostika, lechenie. Irkutsk, 37.
Drogovoz, S. M., Gudzenko, A. P., Butko, Ya. O. et al. (2010). Pobochoe deistvie lekarstv. Kharkiv: SIM, 480.
Rousar, T., Kucera, О., Krivakova, Р. et al. (2009). Evaluation of oxidative status in acetaminophen treated rat hepatocyes in culture. Physiol Res., 58, 239–246.
Gunawan, B. K., Kaplowitz, N. (2007). Mechanism of drug–induced liver disease. Clin. Liver Dis., 11, 459–475.
McDonnell, M. E., Braverman, L. E., Patel, K. P. et al. (2014). Drug–related hepatotoxicity. N. Engl. J. Med., 354, 2191–2193.
Drohovoz, S. M., Pozdniakova, A. Yu., Zaharko, N. V. (2015). Klinichna farmatsiia –Clinical pharmacy, 4, 52–57.
Downloads
Published
Issue
Section
License
Copyright (c) 2017 National University of Pharmacy
This work is licensed under a Creative Commons Attribution 4.0 International License.
Authors who publish with this journal agree to the following terms:- Authors retain copyright and grant the journal right of first publication with the work simultaneously licensed under a Creative Commons Attribution License that allows others to share the work with an acknowledgement of the work's authorship and initial publication in this journal.
- Authors are able to enter into separate, additional contractual arrangements for the non-exclusive distribution of the journal's published version of the work (e.g., post it to an institutional repository or publish it in a book), with an acknowledgement of its initial publication in this journal.
- Authors are permitted and encouraged to post their work online (e.g., in institutional repositories or on their website) prior to and during the submission process, as it can lead to productive exchanges, as well as earlier and greater citation of published work (See The Effect of Open Access).
